Compositions and methods for viral sensitization

Patent metadata

Field	Value
Publication number	US-12195451-B2
Application number	US-202217710386-A
Country	US
Kind code	B2
Filing date	Mar 31, 2022
Priority date	Jan 26, 2015
Publication date	Jan 14, 2025
Grant date	Jan 14, 2025

Abstract

Provided are compounds of Formula III that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.

First claim

What is claimed is:

1. A compound of formula (III):

wherein:
X 5 is linear or branched C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, or C 3 -C 5 cycloalkyl, wherein the C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, and C 3 -C 5 cycloalkyl groups are unsubstituted or substituted with one or more of —SH, —NR x R y , —NR x SO 2 R z , phenyl, naphthyl, 5- to 6-membered heteroaryl, cycloalkyl or heterocycloalkyl, where each phenyl, naphthyl, heteroaryl, cycloalkyl and heterocycloalkyl are unsubstituted or substituted with one or more of —OH, —C 1 -C 6 alkyl, —C 1 -C 6 alkoxy, halogen, —SO 2 C 1 -C 6 alkyl, —CF 3 , —NO 2 , phenyl, benzyl, or —C 1 -C 6 alkyleneC(O)OR x ;
R x is H or C 1 -C 6 alkyl;
R y is H or C 1 -C 6 alkyl;
R z is phenyl, naphthyl, dimethylamino-naphthyl or heteroaryl;
provided that when X 5 is C 1 alkyl substituted with phenyl, the phenyl is substituted, or a pharmaceutically acceptable salt, or stereochemically isomeric form thereof.

2. The compound of claim 1 or a pharmaceutically acceptable salt, or stereochemically isomeric form thereof, wherein X 5 is linear or branched C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 3 -C 5 cycloalkyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and C 3 -C 5 cycloalkyl groups are unsubstituted or substituted with one or more of phenyl, morpholinyl, naphthyl, pyridinyl, furyl, thienyl, triazolyl, oxazolyl, —SH, —NH 2 , or —NR x SO 2 R z .

3. The compound of claim 1 or a pharmaceutically acceptable salt, or stereochemically isomeric form thereof, wherein X 5 is linear or branched C 1 -C 6 alkyl substituted with one or more phenyl, where the phenyl is substituted with one or more of —OMe, —OH, phenyl, Cl, F, —SO 2 Me, —CF 3 , or —NO 2 .

4. The compound of claim 1 or a pharmaceutically acceptable salt, or stereochemically isomeric form thereof, wherein X 5 is linear or branched C 1 -C 6 alkyl substituted with one or more triazolyl, where the triazolyl is substituted with one or more of —C 1 -C 6 alkyleneC(O)OR x or benzyl.

5. The compound of claim 1 or a pharmaceutically acceptable salt, or stereochemically isomeric form thereof, selected from the group consisting of.

6. The compound of claim 1 , or a pharmaceutically acceptable salt, or stereochemically isomeric form thereof, selected from the group consisting of

7. A composition comprising a compound of claim 1 , and one or more pharmaceutically acceptable carriers, diluents or excipients.

Assignees

• Ottawa Hospital Res Inst
• Univ Ottawa
• Ottawa Hospital Research Institute And Univ Of Ottawa

Inventors

• Diallo Jean-Simon
• Boddy Christopher Noyce
• Dornan Mark
• Krishnan Ramya
• Arulanandam Rozanne
• Le Boeuf Fabrice
• Smith Jeffrey
• Macklin Andrew

Classifications

• C07D231/08

  with oxygen or sulfur atoms directly attached to ring carbon atoms · CPC title

• C07D209/48

  with oxygen atoms in positions 1 and 3, e.g. phthalimide · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K31/341

  not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine · CPC title

• A61P35/02

  specific for leukemia · CPC title